Translate
About
Jiangsu Hengrui Medicine Co Ltd (SHG:600276) — investor relations, events, news, and company updates on 6ix.
Latest News
Nov 4 2025
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
Oct 27 2025
Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion
Oct 21 2025
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
Oct 20 2025
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
Sep 24 2025
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
Financials
Revenue
CN¥31.63 B
Market Cap
CN¥375.34 B
P/E Ratio
47.78
EPS
1.18
Dividend Yield
0.35%